Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers.
about
MHC class I-associated peptides derive from selective regions of the human genome.Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers.Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease.Off-the-shelf TCR for graft-versus-leukemia without GVHD.Analysis of the Minor Histocompatibility Antigen Landscape Based on the 1000 Genomes Project
P2860
Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Proteogenomic-based discovery ...... herapy of hematologic cancers.
@en
Proteogenomic-based discovery ...... herapy of hematologic cancers.
@nl
type
label
Proteogenomic-based discovery ...... herapy of hematologic cancers.
@en
Proteogenomic-based discovery ...... herapy of hematologic cancers.
@nl
prefLabel
Proteogenomic-based discovery ...... herapy of hematologic cancers.
@en
Proteogenomic-based discovery ...... herapy of hematologic cancers.
@nl
P2093
P2860
P356
P1433
P1476
Proteogenomic-based discovery ...... therapy of hematologic cancers
@en
P2093
A Rodenbrock
D P Granados
J-P Laverdure
O Caron-Lizotte
P2860
P2888
P304
P356
10.1038/LEU.2016.22
P577
2016-02-09T00:00:00Z